MX2017000059A - Metodos de tratamiento profilactico antivirales y kits de profilaxis previa a la exposicion. - Google Patents

Metodos de tratamiento profilactico antivirales y kits de profilaxis previa a la exposicion.

Info

Publication number
MX2017000059A
MX2017000059A MX2017000059A MX2017000059A MX2017000059A MX 2017000059 A MX2017000059 A MX 2017000059A MX 2017000059 A MX2017000059 A MX 2017000059A MX 2017000059 A MX2017000059 A MX 2017000059A MX 2017000059 A MX2017000059 A MX 2017000059A
Authority
MX
Mexico
Prior art keywords
hsv
prophylaxis
hiv
kits
treatment methods
Prior art date
Application number
MX2017000059A
Other languages
English (en)
Inventor
RAMIREZ Christina
A Checcone Emidio
Original Assignee
Prophylaxis LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prophylaxis LLC filed Critical Prophylaxis LLC
Publication of MX2017000059A publication Critical patent/MX2017000059A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente divulgación proporciona composiciones y métodos para la prevención de la infección por VHS en un individuo seronegativo respecto a VHS. El virus del herpes simple (VHS) se asocia en muchos individuos infectados con recidivas que se manifiestan como herpes labiales y/o herpes genitales, siendo ambos a menudo dolorosos y embarazosos. El VHS tiene también una trascendencia sanitaria significativa ya que la infección por VHS incrementa en un factor de 2-3 el riesgo de que una persona adquiera el virus de la inmunodeficiencia humana (VIH) e incremente el riesgo en un factor de 8 si la persona se expone a VIH poco después de adquirir el VHS. Por lo tanto, con el fin de abordarla epidemia por VIH también es necesario abordar la epidemia por VHS.
MX2017000059A 2014-07-07 2015-07-07 Metodos de tratamiento profilactico antivirales y kits de profilaxis previa a la exposicion. MX2017000059A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462021589P 2014-07-07 2014-07-07
PCT/US2015/039421 WO2016007538A1 (en) 2014-07-07 2015-07-07 Viral prophylaxis treatment methods and pre-exposure prophylaxis kits

Publications (1)

Publication Number Publication Date
MX2017000059A true MX2017000059A (es) 2017-11-08

Family

ID=55016233

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000059A MX2017000059A (es) 2014-07-07 2015-07-07 Metodos de tratamiento profilactico antivirales y kits de profilaxis previa a la exposicion.

Country Status (14)

Country Link
US (1) US10052329B2 (es)
EP (2) EP4342545A2 (es)
JP (3) JP2017527610A (es)
KR (1) KR20170063512A (es)
CN (2) CN114469958A (es)
AU (3) AU2015287994B2 (es)
BR (1) BR112017000285A2 (es)
CA (1) CA2954526C (es)
ES (1) ES2964529T3 (es)
IL (2) IL249938B (es)
MX (1) MX2017000059A (es)
PL (1) PL3166680T3 (es)
SG (2) SG11201700061PA (es)
WO (1) WO2016007538A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11071745B2 (en) 2014-07-07 2021-07-27 Elian Llc Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
EP4342545A2 (en) 2014-07-07 2024-03-27 Elian LLC Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
KR102607599B1 (ko) * 2017-02-08 2023-11-28 바이오트론 리미티드 인플루엔자의 치료 방법
CA3067906A1 (en) * 2017-06-28 2019-01-03 Aicuris Anti-Infective Cures Gmbh Intravaginally applicable devices comprising antiviral compounds
WO2020086705A2 (en) * 2018-10-23 2020-04-30 Eastern Virginia Medical School Pharmaceutical compositions and methods of making on demand solid dosage formulations
WO2020092990A1 (en) * 2018-11-02 2020-05-07 Eastern Virginia Medical School Pharmaceutical compositions and methods of making a patch formulation for transdermal delivery
MX2021010063A (es) * 2019-02-25 2021-11-12 Elian Llc Tratamiento del herpes simplex con una combinación de valaciclovir y famciclovir.
US20210322469A1 (en) * 2020-04-20 2021-10-21 Regents Of The University Of Minnesota Zinc and copper for the prophylaxis and treatment of covid-19

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795721A (en) 1990-06-11 1998-08-18 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of ICP4
ES2284250T3 (es) * 1998-04-21 2007-11-01 Infectio Recherche Inc. Formulaciones para la prevencion o el tratamiento de enfermedades que afectan a la membrana mucosa o la piel, o para la prevencion del embarazo.
GB9819898D0 (en) * 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
US20020091097A1 (en) 2000-09-07 2002-07-11 Bratzler Robert L. Nucleic acids for the prevention and treatment of sexually transmitted diseases
EP1996209B1 (en) * 2006-03-22 2015-11-04 Starpharma Pty Limited Contraceptive composition
WO2009142827A2 (en) 2008-03-28 2009-11-26 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and methods for the treatment of viral infection
US8853223B2 (en) * 2010-09-17 2014-10-07 G2L Touch, Inc. Therapeutic composition to treat lesions caused by herpes simplex virus
ES2551738T3 (es) * 2010-06-11 2015-11-23 Gilead Sciences, Inc. Formulaciones tópicas antivirales para la prevención de la transmisión del VHS-2
WO2012158779A1 (en) * 2011-05-17 2012-11-22 Reprotect, Inc. Reusable intravaginal delivery device, system, and method
EP2734262B1 (en) * 2011-07-20 2018-02-28 Patrick F. Kiser Intravaginal rings for drug delivery
PL2850431T3 (pl) * 2012-05-16 2018-09-28 Immune Design Corp. Szczepionki przeciwko HSV-2
EP4342545A2 (en) 2014-07-07 2024-03-27 Elian LLC Viral prophylaxis treatment methods and pre-exposure prophylaxis kits

Also Published As

Publication number Publication date
AU2020203896A1 (en) 2020-07-02
US10052329B2 (en) 2018-08-21
EP3166680A1 (en) 2017-05-17
AU2015287994B2 (en) 2020-03-12
US20160000797A1 (en) 2016-01-07
JP2017527610A (ja) 2017-09-21
ES2964529T3 (es) 2024-04-08
BR112017000285A2 (pt) 2017-10-31
EP3166680C0 (en) 2023-11-15
EP3166680B1 (en) 2023-11-15
AU2020203896B2 (en) 2022-08-25
CA2954526A1 (en) 2016-01-14
IL249938A0 (en) 2017-03-30
IL273932B2 (en) 2023-07-01
JP2023179575A (ja) 2023-12-19
JP2021138723A (ja) 2021-09-16
IL249938B (en) 2020-04-30
CN106794336A (zh) 2017-05-31
SG10201913641XA (en) 2020-03-30
WO2016007538A1 (en) 2016-01-14
EP4342545A2 (en) 2024-03-27
SG11201700061PA (en) 2017-02-27
CN114469958A (zh) 2022-05-13
AU2015287994A1 (en) 2017-02-02
PL3166680T3 (pl) 2024-03-25
IL273932B1 (en) 2023-03-01
AU2022275517A1 (en) 2023-01-05
CA2954526C (en) 2023-03-07
KR20170063512A (ko) 2017-06-08
CN106794336B (zh) 2022-01-11
IL273932A (en) 2020-05-31
EP3166680A4 (en) 2018-01-17

Similar Documents

Publication Publication Date Title
MX2017000059A (es) Metodos de tratamiento profilactico antivirales y kits de profilaxis previa a la exposicion.
MX2020005187A (es) Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos.
CY1124043T1 (el) Εξουδετερωτικα αντισωματα του ανθρωπινου ιου της ανοσοανεπαρκειας και μεθοδοι χρησης αυτων
CU20170109A7 (es) Derivado de quinoleina para tratar y prevenir infecciones virales
NZ724343A (en) 4’-substituted nucleoside-derivatives as hiv reverse transcriptase inhibitors
MY186414A (en) Human immunodeficiency virus neutralizing antibodies
EP3774775C0 (en) 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNO DEFICIENCY VIRUS REPLICATION
CA2998646C (en) 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
ECSP12012106A (es) Terapia antiviral
MX2017002972A (es) Pirrolopirimidinas para usarse en la infeccion por el virus de la gripe.
IN2013MU01749A (es)
EA201691443A1 (ru) Накожное восстановление иммунобаланса
CL2017000714A1 (es) Composiciones farmacéuticas de acción prolongada
PH12019550039A1 (en) Dihydropyrimidine compound and preparation method and use thereof
MX369474B (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad.
MA53973A (fr) Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
BR112014003989A2 (pt) composto, composições e métodos para inibir a replicação do hiv-1 em paciente, para tratar pacientes infectados com hiv/aids e para profilaxia de pré-exposição para tratar paciente e para prevenir a transmissão de pessoa infectada para pessoa não infectada
MX2016002903A (es) Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah.
PE20160596A1 (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana
CO2018005952A2 (es) Método para la destoxificación de proteínas del gluten provenientes de granos de cereal y usos de las mismas en el campo médico
MA40805A (fr) Compositions pharmaceutiques à action prolongée contre l'hépatite c
TW201613939A (en) Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
BR112015021947A2 (pt) formulações de baixa glicerina para tratamento e prevenção de hiv